Dosage protocol · Metabolic & Weight Loss
Tirzepatide 15 mg
Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
- Reconstitute: Add 2.0 mL bacteriostatic water → 7.5 mg/mL concentration.
- Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
- Easy measuring: At 7.5 mg/mL, 1 unit = 0.01 mL = 75 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.
BAC water2.0mL
Concentration7.5mg/mL
Per unit (0.01 mL)75mcg
Reconstitution
Tirzepatide dosage chart
Tirzepatide dosage chart
| Phase | Week | Draw |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 33 units × 1 injection0.33 mL |
| Weeks 5–8 | 5 mg | 67 units × 1 injection0.67 mL |
| Weeks 9–12 | 7.5 mg | 100 units × 1 injection1.0 mL |
| Weeks 13–16 | 10 mg | 67 units × 2 injections0.67 mL |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
Tirzepatide is a synthetic peptide medication that acts as a dual agonist at two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.[1] Incretins are gut-derived signals that help coordinate insulin release, appetite, and glucose handling after meals, and tirzepatide's engineered structure allows once-weekly subcutaneous dosing.
In the United States, tirzepatide is sold under two FDA-approved brand names with distinct indications: Mounjaro for improving glycemic control in adults with type 2 diabetes, and Zepbound for chronic weight management in adults with obesity or overweight plus a weight-related condition, as well as for moderate-to-severe obstructive sleep apnea in adults with obesity.[2] These are genuine drug approvals with full prescribing labels, not general "research peptide" status.
Benefits & side effects
The SURPASS trial program evaluated tirzepatide in type 2 diabetes; in SURPASS-2, it produced larger A1C and weight reductions than semaglutide 1 mg over 40 weeks, with gastrointestinal effects common in both groups.[4] Other SURPASS trials compared it against insulin-based regimens, generally supporting glycemic benefits in the populations studied.
For weight management, SURMOUNT-1 reported substantial dose-related weight reductions over 72 weeks in adults with obesity or overweight without diabetes, and SURMOUNT-2 extended this to people with obesity and type 2 diabetes.[5] A separate trial supporting the sleep apnea indication measured reduced apnea-hypopnea index in people with obesity. A withdrawal study (SURMOUNT-4) found people who stopped tirzepatide after initial treatment regained weight, underscoring these are treatment effects requiring continued use, not a one-time fix. Claims about anti-aging or performance enhancement are not supported by this trial base.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.
1
Reconstitution
mg
mL
Concentration—
Per unit (0.01 mL)—
Per 10 units (0.1 mL)—
2
Your dose
Doses per vial—
Vial lasts—
Draw to
— units
=
—
